孕期接种Tdap疫苗阻断百日咳发病率二十年持续上升趋势
该研究基于以色列1998至2019年实验室确诊百日咳病例构建统计模型,识别出四年周期性,并发现2002至2014年发病率上升325%;2015年引入孕期常规接种Tdap后,发病率较模型预测下降59.7%(95%CI:57.7-61.6%),住院下降49.5%(36.0-61.6%),≤2月龄婴儿降幅更大。
要点
- 以色列百日咳发病率呈四年周期性,2002至2014年上升325%。
- 2015年孕期常规接种Tdap后发病率较预测下降59.7%,住院下降49.5%。
- ≤2月龄婴儿发病率下降71.2%,住院下降58.4%。
核心结论
- 孕期接种Tdap疫苗是控制百日咳的有前景策略。
- 由于百日咳周期性稳定,公共卫生决策者应持续实施该策略并在预期高峰年加强。
研究设计与样本
- 基于以色列1998至2019年实验室确诊百日咳病例构建简单统计模型,校准并检验模型以捕捉发病率时间模式。
主要发现
- 模型识别出过去二十年清晰的四年周期性,与疫苗前时代观察到的周期一致。
- 模型显示2002至2014年百日咳发病率上升325%。
- 2015年孕期常规接种Tdap后,发病率较模型预测下降59.7%(95%CI:57.7-61.6%),住院下降49.5%(36.0-61.6%)。
- ≤2月龄婴儿发病率下降71.2%(65.6-76.1%),住院下降58.4%(39.6-72.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 发病率下降不能完全归因于新引入的疫苗接种政策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pertussis incidence in developed countries, including Israel, has increased over the past two decades despite the addition of two booster doses in children. However, as pertussis is characterized by a multi-annual periodicity, and since clinical diagnosis can miss cases, determining disease trends at the population level is challenging. To bridge this gap, we developed a simple statistical model to capture the temporal patterns of pertussis incidence in Israel. Our model was calibrated and tested using laboratory-confirmed cases of pertussis for the Israeli population between 1998 and 2019. The model identifies a clear four-year periodicity of pertussis incidence over the past two decades that is identical to the one observed in the pre-vaccine era. Accounting for this periodicity, the model shows a 325% increase in pertussis incidence from 2002 to 2014. These multi-year trends were interrupted shortly after the introduction of routine immunization of Tdap vaccine in pregnancy in 2015, after which we found a 59.7% (95% CI: 57.7-61.6%)decline in pertussis incidence and a 49.5% (36.0-61.6%) decline in hospitalizations compared to the model's projection. While this sharp decline cannot be fully attributed to the newly introduced vaccination policy, sharper reductions of 71.2% (65.6-76.1%) in incidence and 58.4% (39.6-72.7%) in hospitalizations, have been observed in infants of age two months and below - young infants that have yet to become vaccinated and are more likely to be protected by maternal vaccination. Our work suggests that Tdap vaccination during pregnancy is a promising policy for controlling pertussis. Furthermore, due to the stable periodicity of pertussis, public health decision-makers should invest continuous efforts in the implementation of this strategy with additional reinforcement in expected peak years.
引用
- Langsam D, Anis E, Haas EJ, et al. Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis. Vaccine. 2020. PMID: 32070682. doi:10.1016/j.vaccine.2020.01.095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。